10955 Vista Sorrento Parkway
Suite 200
San Diego, CA 92130
United States
858-751-4493
https://www.januxrx.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 64
Nombre | Título | Paga | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. David Alan Campbell Ph.D. | President, CEO & Director | 1,04M | N/A | 1960 |
Mr. Charles M. Winter | Chief Technical Officer | 590,4k | N/A | 1969 |
Mr. Byron Robinson J.D., Ph.D. | Chief Strategy Officer | 723k | N/A | 1965 |
Dr. Tommy Diraimondo Ph.D. | Chief Scientific Officer | N/A | N/A | 1986 |
Mr. James Pennington | General Counsel | N/A | N/A | N/A |
Ms. Brenda Van Vreeswyk | Head of Human Resources | N/A | N/A | N/A |
Mr. Andy Hollman Meyer | Chief Business Officer | N/A | N/A | 1984 |
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
El ISS Governance QualityScore de Janux Therapeutics, Inc., a día 1 de mayo de 2024, es 10. Las puntuaciones base son Auditoría: 8; Tablero: 10; Derechos de los accionistas: 8; Compensación: 9.